Abstract
Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylating Agent Exposure Who Achieved Remission
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have